CD markers polymorphisms as prognostic biomarkers in hematological malignancies.

IF 3.1 Q2 ONCOLOGY

Oncology Reviews Pub Date : 2020-07-14 eCollection Date: 2020-07-06 DOI:10.4081/oncol.2020.466

Saeid Shahrabi, Majid Ghanavat, Masumeh Maleki Behzad, Daryush Purrahman, Najmaldin Saki

{"title":"CD markers polymorphisms as prognostic biomarkers in hematological malignancies.","authors":"Saeid Shahrabi, Majid Ghanavat, Masumeh Maleki Behzad, Daryush Purrahman, Najmaldin Saki","doi":"10.4081/oncol.2020.466","DOIUrl":null,"url":null,"abstract":"The clusters of differentiation (CD) are surface molecules used for immunophenotyping of cells. The expression of CD markers is widely used to classify hematological malignancies, including leukemia and lymphoma. Single nucleotide polymorphisms (SNPs) are crucial genetic changes that can be associated with abnormal expression and function of CD markers. In this paper, we assess the prognostic effect of CD markers' SNPs in hematological malignancies. Materials and methods and relevant literature was identified by a PubMed search (2001-2019) of English language papers using the following terms: 'polymorphism', 'CD marker', 'leukemia', 'lymphoma', 'prognosis', 'CD marker', and 'polymorphism'. Many studies have demonstrated the effects of CD markers' polymorphisms on risk of hematological malignancies. Also, SNPs of CD markers can be related with clinicopathological features, invasiveness, and response to therapy of these disorders. Considering the importance of SNPs in the expressions of CD markers, these genetic changes could be used as potential prognostic biomarkers in hematological malignancies. It is hoped that the evaluation of SNPs in CD markers will enable early diagnosis, prognosis, and detection of response to treatment. However, better understanding of SNPs in CD markers that are involved in hematological malignancies requires further studies on different populations of the worldwide.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2020-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/96/onco-14-2-466.PMC7385526.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2020.466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/7/6 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

The clusters of differentiation (CD) are surface molecules used for immunophenotyping of cells. The expression of CD markers is widely used to classify hematological malignancies, including leukemia and lymphoma. Single nucleotide polymorphisms (SNPs) are crucial genetic changes that can be associated with abnormal expression and function of CD markers. In this paper, we assess the prognostic effect of CD markers' SNPs in hematological malignancies. Materials and methods and relevant literature was identified by a PubMed search (2001-2019) of English language papers using the following terms: 'polymorphism', 'CD marker', 'leukemia', 'lymphoma', 'prognosis', 'CD marker', and 'polymorphism'. Many studies have demonstrated the effects of CD markers' polymorphisms on risk of hematological malignancies. Also, SNPs of CD markers can be related with clinicopathological features, invasiveness, and response to therapy of these disorders. Considering the importance of SNPs in the expressions of CD markers, these genetic changes could be used as potential prognostic biomarkers in hematological malignancies. It is hoped that the evaluation of SNPs in CD markers will enable early diagnosis, prognosis, and detection of response to treatment. However, better understanding of SNPs in CD markers that are involved in hematological malignancies requires further studies on different populations of the worldwide.

查看原文本刊更多论文

CD标记物多态性作为血液系统恶性肿瘤的预后生物标志物。

分化簇(CD)是用于细胞免疫分型的表面分子。CD标记物的表达被广泛用于血液系统恶性肿瘤的分类，包括白血病和淋巴瘤。单核苷酸多态性(SNPs)是与CD标记物异常表达和功能相关的重要遗传变化。在本文中，我们评估了CD标记物snp在血液恶性肿瘤中的预后作用。材料、方法和相关文献通过PubMed检索(2001-2019)英文论文，使用以下术语:“多态性”、“CD标记物”、“白血病”、“淋巴瘤”、“预后”、“CD标记物”和“多态性”。许多研究已经证明了CD标记物多态性对血液系统恶性肿瘤风险的影响。此外，CD标记物的snp可能与这些疾病的临床病理特征、侵袭性和治疗反应有关。考虑到snp在CD标记物表达中的重要性，这些遗传变化可以作为血液系统恶性肿瘤的潜在预后生物标志物。我们希望通过对CD标记物中snp的评估来实现早期诊断、预后和对治疗反应的检测。然而，为了更好地了解与血液系统恶性肿瘤相关的CD标记物的snp，需要对全球不同人群进行进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology Reviews ONCOLOGY-

CiteScore

6.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.